Werewolf Net Income Per Share from 2010 to 2026

HOWL Stock  USD 0.68  0.02  3.03%   
Werewolf Therapeutics Net Loss yearly trend continues to be quite stable with very little volatility. The value of Net Loss is projected to decrease to -1.96. From the period between 2010 and 2026, Werewolf Therapeutics, Net Loss regression line of its data series had sample variance of  0.60 and sample variance of  0.60. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(1.87)
Current Value
(1.96)
Quarterly Volatility
0.77567206
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Werewolf Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Werewolf Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 1.5 M, Depreciation And Amortization of 1.1 M or Interest Expense of 5.6 M, as well as many indicators such as Price To Sales Ratio of 32.15, Dividend Yield of 0.0 or PTB Ratio of 0.95. Werewolf financial statements analysis is a perfect complement when working with Werewolf Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Werewolf Stock
Check out the analysis of Werewolf Therapeutics Correlation against competitors.
For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.
Historical Net Income Per Share data for Werewolf Therapeutics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Werewolf Therapeutics represents a compelling investment opportunity.

Latest Werewolf Therapeutics' Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of Werewolf Therapeutics over the last few years. It is Werewolf Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Werewolf Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

Werewolf Net Income Per Share Regression Statistics

Arithmetic Mean(0.91)
Coefficient Of Variation(85.44)
Mean Deviation0.66
Median(0.38)
Standard Deviation0.78
Sample Variance0.60
Range2.325
R-Value(0.75)
Mean Square Error0.28
R-Squared0.56
Significance0.0005
Slope(0.12)
Total Sum of Squares9.63

Werewolf Net Income Per Share History

2026 -1.96
2025 -1.87
2024 -1.63
2023 -1.05
2022 -1.86
2021 -2.71
2020 -0.52

About Werewolf Therapeutics Financial Statements

Werewolf Therapeutics investors utilize fundamental indicators, such as Net Income Per Share, to predict how Werewolf Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss(1.87)(1.96)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Werewolf Therapeutics is a strong investment it is important to analyze Werewolf Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Werewolf Therapeutics' future performance. For an informed investment choice regarding Werewolf Stock, refer to the following important reports:
Check out the analysis of Werewolf Therapeutics Correlation against competitors.
For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. Market participants price Werewolf higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Werewolf Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.62)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.41)
Return On Equity
(1.22)
Investors evaluate Werewolf Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Werewolf Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Werewolf Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Werewolf Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.